Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy

被引：0
作者：
Megu Yamaguchi Baden
Akihisa Imagawa
Norio Abiru
Takuya Awata
Hiroshi Ikegami
Yasuko Uchigata
Yoichi Oikawa
Haruhiko Osawa
Hiroshi Kajio
Eiji Kawasaki
Yumiko Kawabata
Junji Kozawa
Akira Shimada
Kazuma Takahashi
Shoichiro Tanaka
Daisuke Chujo
Tomoyasu Fukui
Junnosuke Miura
Kazuki Yasuda
Hisafumi Yasuda
Tetsuro Kobayashi
Toshiaki Hanafusa
机构：
[1] Osaka University,Department of Metabolic Medicine, Graduate School of Medicine
[2] Osaka Medical College,Department of Internal Medicine (I)
[3] Nagasaki University Graduate School of Biomedical Sciences,Department of Endocrinology and Metabolism
[4] International University of Health and Welfare Hospital,Department of Diabetes, Endocrinology and Metabolism
[5] Kindai University Faculty of Medicine,Department of Endocrinology, Metabolism and Diabetes
[6] Tokyo Women’s Medical University Medical Center East,Department of Endocrinology and Diabetes, School of Medicine
[7] Saitama Medical University,Department of Laboratory Medicine
[8] Ehime University School of Medicine,Department of Diabetes, Endocrinology, and Metabolism
[9] Center Hospital of the National Center for Global Health and Medicine,Diabetes Center
[10] Shin-Koga Hospital,Faculty of Nursing and Graduate School of Nursing
[11] Iwate Prefectural University,Department of Internal Medicine, Division of Diabetes and Endocrinology
[12] Ai Home Clinic Toshima,Diabetes Center
[13] Showa University School of Medicine,Department of Metabolic Disorder, Diabetes Research Center, Research Institute
[14] Tokyo Women’s Medical University School of Medicine,Division of Health Sciences, Department of Community Health Sciences
[15] National Center for Global Health and Medicine,undefined
[16] Kobe University Graduate School of Health Sciences,undefined
[17] Okinaka Memorial Institute for Medical Research,undefined
[18] Sakai City Medical Center,undefined
来源：
Diabetology International | 2019年 / 10卷
关键词：
Nivolumab; Pembrolizumab; Anti-PD-1 antibody; Fulminant type 1 diabetes; Type 1 diabetes; Immune-checkpoint inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：58 / 66
页数：8
相关论文
共 343 条
  • [1] Atkinson MA(2014)Type 1 diabetes Lancet 383 69-82
  • [2] Eisenbarth GS(2000)A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group N Engl J Med 342 301-307
  • [3] Michels AW(2007)Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners Nat Clin Pract Endocrinol Metab 3 36-45
  • [4] Imagawa A(2016)Risk factors for sudden death and cardiac arrest at the onset of fulminant type 1 diabetes mellitus Diabetol Int 7 281-288
  • [5] Hanafusa T(2015)The future of immune checkpoint therapy Science 348 56-61
  • [6] Miyagawa J(2016)Immune-related adverse events with immune checkpoint blockade: a comprehensive review Eur J Cancer 54 139-148
  • [7] Matsuzawa Y(2016)Immune checkpoint therapy and type 1 diabetes Diabetol Int 7 221-227
  • [8] Hanafusa T(2003)Fulminant type 1 diabetes: a nationwide survey in Japan Diabetes Care 26 2345-2352
  • [9] Imagawa A(2004)Differences in the contribution of HLA-DR and -DQ haplotypes to susceptibility to adult- and childhood-onset type 1 diabetes in Japanese patients Diabetes 53 2684-2690
  • [10] Baden MY(2008)Uniformity in clinical and HLA-DR status regardless of age and gender within fulminant type 1 diabetes Diabetes Res Clin Pract 82 233-237
12345678910